ClinicalTrials.gg

Chronic Limb-Threatening Ischemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 358 studies for Chronic Limb-Threatening Ischemia across more than 10 countries. 73 are recruiting or about to start. 294 of them are mainly about Chronic Limb-Threatening Ischemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
157
Status unknown
70
Recruiting
51
Terminated
30
Not yet recruiting
17
Active, not recruiting
16

Phase

Phase 2
71
Phase 1
49
Phase 3
28
Phase 4
20
Early Phase 1
5

Where

United States
105
Germany
32
Italy
24
China
23
United Kingdom
23
France
22

Who develops what

Add Chronic Limb-Threatening Ischemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.Etribnabdione 25 mg BID · VivaCell Biotechnology España · Phase 2 registry mapping onlyNCT06774040 Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease — primary endpoint: Incidence and severity of Treatment Emergent Adverse Events (TEAEs) · 30 enrolled
  • 30 Jun 2027 est.APAC - dose level 0.50 mg/kg, · Aplagon Oy · Phase 2 main aimNCT07352800 Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia — primary endpoint: Primary endpoint - Part A: Occurrence and severity of treatment-emergent adverse events (TEAEs) · 42 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Chronic Limb-Threatening Ischemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Factor Xa inhibitors 1 open

Coming up

27studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger. 3 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (12%) take healthy volunteers.

Recruiting studies that take each age, of 51
AgeWomenMen
103 (6%)3 (6%)
1842 (82%)42 (82%)
3046 (90%)46 (90%)
4049 (96%)49 (96%)
5049 (96%)49 (96%)
6551 (100%)51 (100%)
7549 (96%)49 (96%)
8547 (92%)47 (92%)

Across all 358 studies, recruiting or not: 5% stop at 75 or younger and 2% at 65; 6% take children; 0% are for women only and <1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Chronic Limb-Threatening Ischemia studies take

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase33 mo19–85 · 72 studies——
Observational34 mo22–59 · 52 studies—41 mo22–60 · 47 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Stopped1

Studies

Recruiting first, then most recently updated. Showing 50 of 358. Browse all 358 → or search them.